Racial Differences in Vagal Control of Glucose Homeostasis

Phase 1

Completed

Interventions: Drug: Galantamine
Drug: Placebo Oral Capsule
Drug: Intralipid
Drug: Heparin

Brief Summary: The investigators will test the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity and reduce oxidation in AAW compared to whites.

Detailed Description: Obesity has a greater detrimental impact on the health of African American women (AAW) than on any other racial or gender group. Nearly 80% of AAW are overweight or obese. Reduced insulin sensitivity is more prevalent among AAW as compared to white women and men of both races. This condition puts AAW at increased risk for the development of type 2 diabetes mellitus. The exact mechanism underlying these pathophysiological differences remains unknown. The investigators have found that obese AAW have decreased parasympathetic nerve (PNS) activity compared to whites and recent studies in animal models showed that the PNS confers protection against oxidative stress. In our AA cohort, PNS activity was directly correlated with insulin sensitivity in obese AAW even after controlling for differences in age, blood pressure and visceral adiposity. Equally important, the investigators also showed that the decrease in insulin sensitivity was associated with increased oxidative stress as measured by plasma levels of F2-isoprostanes. Taken together these findings lead us to hypothesize that the decreased PNS activity in obese AAW compared to white women has deleterious effects on oxidative stress and insulin sensitivity.The investigators will test the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity and reduce oxidation in AAW compared to whites.

Recruitment & Eligibility

Inclusion Criteria

Female
African American or white (race will be self-defined, but only subjects who report both parents of the same race will be included)
18-60 years old
BMI 30-45 Kg/m2
Not pregnant or breastfeeding

Exclusion Criteria

Pregnant or breastfeeding
Diabetes diagnosis (defined by the American Diabetes Association (ADA) criteria)38
Cardiovascular disease such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy.
Arrhythmia (first-, second-, and third-degree atrioventricular (AV) block)
Significant weight change >5% in the past 3 months
Impaired hepatic function (AST and/or Alanine transaminase (ALT) > one and one half times (1.5X) upper limit of normal range)
Impaired renal function (eGFR <60ml/min)
Users of strong inhibitors of Cytochrome P450 3A4 (CYP3A4) or cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6)
Users of other acetylcholinesterase inhibitors such as pyridostigmine or bethanechol
History of alcohol or drug abuse
Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study
Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study

Arm && Interventions

Group	Intervention	Description
Placebo then Galantamine 16 mg	Placebo Oral Capsule	Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
Galantamine 16 mg then placebo	Placebo Oral Capsule	Galantamine 16 mg po one time dose then placebo on 2nd visit
Galantamine 16 mg then placebo	Galantamine	Galantamine 16 mg po one time dose then placebo on 2nd visit
Galantamine 16 mg then placebo	Intralipid	Galantamine 16 mg po one time dose then placebo on 2nd visit
Galantamine 16 mg then placebo	Heparin	Galantamine 16 mg po one time dose then placebo on 2nd visit
Placebo then Galantamine 16 mg	Galantamine	Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
Placebo then Galantamine 16 mg	Intralipid	Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
Placebo then Galantamine 16 mg	Heparin	Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit

Primary Outcome Measures

Name	Time	Method
Change in Oxidative Stress: Baseline to 2 Hours	Baseline to 2 hours	Measure F-2 isoprostanes as a marker of oxidation
Change in Oxidative Stress: Baseline to 4 Hours	Baseline to 4 hours	Measure F-2 isoprostanes as a marker of oxidation

Secondary Outcome Measures